INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...

These findings demonstrate that the FRα is a target of the immune system in breast and ovarian cancer patients. Understanding which antigens are targeted by the immune system may be important for ...

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer.

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor ...

Mirvetuximab soravtansine (Elahere) is available on the NHS. It is a possible treatment for folate receptor-alpha positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and ...

AbbVie Inc (NYSE:ABBV) released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive ...

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, ...

Optimal surgical debulking to R0 remains a dominant prognostic determinant in ovarian cancer, while PARP inhibitor maintenance has become integral for BRCA-mutant and HRD-positive tumors.

Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may ...

Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FR‑alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, ...